Rocket Pharmaceuticals, Inc. (RCKT)

Name: Rocket Pharmaceuticals, Inc. (RCKT) annual fundamentals
Creator: TickerFacts
License: https://creativecommons.org/publicdomain/zero/1.0/

Build a valuation ↗↓ Download CSV

SEC name ROCKET PHARMACEUTICALS, INC. · CIK 0001281895 · Nasdaq · Pharmaceutical Preparations

Sector Manufacturing
Incorporated DE
Fiscal year ends Dec 31

For the year ended 2025-12-31, Rocket Pharmaceuticals, Inc. reported revenue of $0. Over the twelve months to 2026-06-30, revenue was $0.

Key ratios (year ended 2025-12-31)

-80.5%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-06

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period ended	TTM to 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31
Revenue	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
R&D Expense	$124.37M	$142.01M	$171.24M	$186.34M	$165.57M	$125.48M	$105.44M	$57.91M	$53.27M	$14.92M	$5.99M
Operating Income	-$191.64M	-$231.75M	-$273.20M	-$259.66M	-$224.34M	-$167.25M	-$134.30M	-$76.15M	-$71.16M	-$19.77M	-$7.57M
Depreciation & Amortization	$7.60M	$8.90M	$7.20M	$4.90M	$3.90M	$3.20M	$1.15M	$426.0K	$330.0K	n/a	n/a
EBITDA	-$184.04M	-$222.85M	-$266.00M	-$254.76M	-$220.44M	-$164.05M	-$133.16M	-$75.72M	-$70.83M	n/a	n/a
Net Income	-$17.25M	-$223.12M	-$258.75M	-$245.59M	-$221.86M	-$169.07M	-$139.70M	-$77.27M	-$74.52M	-$19.58M	-$7.57M
EPS (Diluted)	n/a	-$2.01	-$2.73	-$2.92	-$3.26	-$2.67	-$2.52	-$1.58	n/a	n/a	n/a
Total Assets	$423.10M	$330.45M	$527.70M	$566.34M	$551.81M	$497.02M	$590.82M	$372.12M	$251.31M	$20.15M	$129.65M
Total Liabilities	$54.27M	$53.23M	$64.47M	$73.77M	$62.12M	$42.30M	$87.31M	$64.82M	$57.28M	$4.63M	$56.48M
Shareholders' Equity	$368.83M	$277.22M	$463.23M	$492.57M	$489.69M	$454.72M	$503.52M	$307.30M	$194.04M	$15.52M	$8.37M
Cash & Equivalents	$224.51M	$77.56M	$163.63M	$55.90M	$140.52M	$232.69M	$297.10M	$185.38M	$111.36M	$18.14M	$29.80M
Operating Cash Flow	-$170.27M	-$190.01M	-$209.72M	-$194.92M	-$178.14M	-$121.16M	-$74.64M	-$64.66M	-$53.79M	-$15.96M	-$5.50M
Capital Expenditures	$127.0K	$440.0K	$5.86M	$16.44M	$8.36M	$7.62M	$20.61M	$23.27M	$1.45M	$760.0K	$335.0K
Free Cash Flow	-$170.39M	-$190.45M	-$215.59M	-$211.35M	-$186.50M	-$128.78M	-$95.25M	-$87.93M	-$55.24M	-$16.72M	-$5.84M
Share Repurchases	n/a	n/a	n/a	n/a	n/a	$0	$72.0K	$0	$0	$0	$0
Shares Outstanding	109.54M	108.32M	106.45M	90.28M	79.12M	64.51M	61.00M	54.77M	45.14M	6.80M	6.75M
Weighted Average Diluted Shares	n/a	111.12M	94.81M	84.01M	68.15M	63.24M	55.38M	49.01M	n/a	n/a	n/a
EPS (Basic)	n/a	-$2.01	-$2.73	-$2.92	-$3.26	-$2.67	-$2.52	-$1.58	n/a	n/a	n/a

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView